Celltrion Company Profile

07:52 EDT 18th March 2018 | BioPortfolio

Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost structure and strategic location in the rapidly growing Asian pharmaceutical markets make us an ideal choice for clients seeking world-class contract manufacturing services.
Celltrion's 23-acre manufacturing operation is located at the center of the high-technology park in Songdo New City, a new high-technology complex in the Incheon Metropolitan City , South Korea. The Celltrion facility is in close proximity to both the Incheon International Airport and downtown Seoul. Construction of Celltrion's 50,0000-liter capacity biopharmaceutical manufacturing facility, which is expected to be ready for commercial operation by early 2006, is being designed to comply with the cGMP (current Good Manufacturing Practices) Standards of the U.S. Food and Drug Administration and EMEA. The capacity can be quickly expanded to 150,000 liters based on client demand.


13-6 Songdo-Dong
Icheon City


Phone: 82 32-850-5000
Fax: 82 32-850-5040

News Articles [50 Associated News Articles listed on BioPortfolio]

Hikma to sell Celltrion's Rituxan biosimilar in Africa, Middle East

The London-based generics company already markets in the MENA region two other copycat biologics developed by Celltrion.

Why Booming Celltrion Started Crashing Last Week

Celltrion, the little-known South Korean biotech company that surged into the ranks of the world's most-traded stocks at the start of 2018, may finally be coming down to Earth.

Positive phase III switching results for Celltrion’s infliximab biosimilar

Results of a phase III extension study have shown that Celltrion Healthcare’s (Celltrion) infliximab biosimilar (CT-P13) is shown to be comparable in efficacy and safety to Johnson & Johnson/Mer...

Safe to switch from Rituxan to our biosimilar in RA, says Celltrion

Korean drugmaker Celltrion Healthcare has presented data supporting switching to its biosimilar version…

FDA warning letter threatens Celltrion's valuable Inflectra franchise

Pfizer’s manufacturing partner in South Korea Celltrion has received a warning letter from the US FDA…

Green light for Celltrion’s Herceptin biosimilar

The European Commission has approved Celltrion Healthcare’s Herzuma, a biosimilar of Roche/Genentech’s blockbuster Herceptin.

Trastuzumab biosimilars receive EMA and ANVISA approval

Trastuzumab products from Celltrion Healthcare (Celltrion) and Biocon/Mylan have received approval in Europe and Brazil.

Celltrion slammed with US FDA warning at biosimilar site

Celltrion says supply of Pfizerâs Inflectra is secure, despite receiving a US FDA warning letter at its biosimilar production plant in Korea.

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis

A new subcutaneous infliximab formulation is being developed by Celltrion, Inc. as an alternative to the intravenous regimen where subcutaneous infliximab injection typically takes less th...

Companies [5 Associated Companies listed on BioPortfolio]

Celltrion Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltr...

Celltrion, Inc.

Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development capabilities in biosimilar monoclonal antibodies (mA...


Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost ...

Teva Pharmaceutical Industries Ltd. and Celltrion, Inc.

Celltrion Healthcare

Satellite symposium 3a: Remsima™, the 1st biosimilar monoclonal antibody, Friday 20 February 07:15-08:15

More Information about "Celltrion" on BioPortfolio

We have published hundreds of Celltrion news stories on BioPortfolio along with dozens of Celltrion Clinical Trials and PubMed Articles about Celltrion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celltrion Companies in our database. You can also find out about relevant Celltrion Drugs and Medications on this site too.

Quick Search


Relevant Topic

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Corporate Database Quicklinks

Searches Linking to this Company Record